Vanguard Capital Management
LRMR icon

Vanguard Capital Management’s Larimar Therapeutics LRMR Stock Holding History

Vanguard Capital Management’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.07M Buy
2,974,901
+108,552
+4% +$431K ﹤0.01% 2875
2026
Q1 		$12.9M Buy
+2,866,349
New +$11.5M ﹤0.01% 2588

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Vanguard Capital Management's LRMR Position: Q2 2026 in Review

Vanguard Capital Management increased its Larimar Therapeutics (LRMR) stake by 3.8% in Q2 2026, buying an estimated $431K and bringing the position to 2,974,901 shares worth $9.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2875.

Vanguard Capital Management first reported a position in LRMR in Q1 2026 and has held it in 2 quarters since. The position peaked at $12.9M in Q1 2026. 161 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Vanguard Capital Management held 2,974,901 shares of Larimar Therapeutics worth $9.07M as of Q2 2026.
  • Vanguard Capital Management bought 108,552 Larimar Therapeutics shares in Q2 2026, an estimated $431K.
  • Larimar Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #2875 holding.
  • Vanguard Capital Management first reported a position in Larimar Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Larimar Therapeutics position peaked at $12.9M in Q1 2026.
  • 161 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.